Pharmaceutical Raw Material Entecavir Powder CAS 142217-69-4 with Best Price

Min.Order / FOB Price:Get Latest Price

1 Gram	FOB Price: USD 10.0000

1 Gram

FOB Price: USD 10.0000

Min.Order :1 Gram
Purity: 99%
Payment Terms : T/T,,Other

Keywords

Entecavir 142217-69-4 Pharmaceutical

Quick Details

Appearance:White powder
Application:Entecavir is a new generation of guanine nucleoside analogue oral medicine for the treatment of hepatitis B virus infection. It is mainly used for the treatment of chronic type B with active viral rep
PackAge:bag
ProductionCapacity:10|Kilogram|Day
Storage:-20°C
Transportation:air

Superiority:

purity min99%

Large volume discount

Our advantage:
We have PEPTIDES and SARMS WAREHOUSE IN USA and Euro, you can receive order with 3 days without any customs problems.
We offer drop ship to your end clients in worldwide.

Why Choose us:
1). We have our own GMP lab .
2). Warehouses in USA and Euro to support your urgent need.
3). We can customize Peptides and Test Report HPLC and MS are available.
4). / Bank Transfer / Credit Card / Bitcoin / T/T in Advance / LC @ SIGHT / Paypal for your option.

Details:

Product description

Product name	Entecavir
CAS No.	142217-69-4
Molecular Formula	C12H15N5O3
Molecular weight	277.28
Grade Standard	Medicine Grade
COA	Avaliable

Product introduction

Entecavir is a cyclopentyl guanosine analog launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection, and it is the third nucleoside or nucleotide analog to be marketed for this indication. Lamivudine, a deoxythiacytosine analog, and adefovir dipivoxil, a nucleotide analog, have been marketed since 1998 and 2002, respectively. Entecavir and adefovir are specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections. In mammalian cells, entecavir is efficiently phosphorylated to the active triphosphate form, which competes with the natural substrate deoxyguanosine triphosphate and functionally inhibits all three activities of the HBV polymerase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA.The most common adverse events associated with the use of entecavir are similar to those typically seen with HBV therapy and include headache, abdominal pain, diarrhea, fatigue, and dizziness.